Table 1 Summary of baseline variables

Female, n (%)

Male, n (%)

13 (26)

37(74)

17 (34)

33(66)

0.383

Weight (kg), Mean (SD)

21.9(9.8)

20.19(8.05)

0.768

Height (cm), Mean (SD)

110.8(17.9)

104.9(16.2)

0.816

Blood Pressure (BP) (mmHg)

Systolic blood pressure (SBP), Mean (SD)

106(12)

108(16)

0.331

Diastolic blood pressure (DBP), Mean (SD)

69(12)

69(13)

0.996

Age at onset

< 1

2(4)

3(6)

0.761

1–5 years

32(64)

33(66)

5–10 years

14(28)

14(28)

> 10 years

2(4)

0(0)

Age at enrolment, Median (IQR)

4.25 (3-7.25)

4.0 (2.37-6)

0.08

Initial symptoms

Edema

49(98)

50(100)

1.000

Hypertension

10(20)

21(42)

0.017

Decreased urine output

21(42)

27(54)

0.230

Spontaneous bacterial peritonitis

4(8)

7(14)

0.338

Cumulative dose(mg/kg), median (IQR)

239(148,370.2)

398(183.5,488)

0.111

Steroids side effects

Weight gain

13(26)

13(26)

1.000

Short stature

3(6)

10(20)

0.037

Cataract

4(8)

7(14)

0.338

Glaucoma

1(2)

2(4)

1.000

Hypertension

23(46)

43(86)

0.000043

Hyperglycaemia

1(2)

1(2)

1.000

Cushingoid facies

26(52)

38(76)

0.012

Acanthosis

3(6)

9(18)

0.065

Immunosuppression

0

2(4)

0.495

Gastritis

5(10)

10(20)

0.161

Hirsutism

6(12)

19(38)

0.003

NS related complications

Peritonitis

6(12)

14(28)

0.046

Cellulitis

5(10)

14(28)

0.022

Pneumonia

2(4)

3(6)

1.000

Cerebral venous sinus thrombosis (CSVT)

0

4(8)

0.117

Deep vein thrombosis (DVT)

0

1(2)

1.000

Pulmonary thromboembolism (PRES)

0

1(2)

1.000

Acute kidney injury (AKI)

2(4)

3(6)

1.000

Lab investigations

Nephrotic range proteinuria

39(78)

43(86)

0.297

Serum albumin

> 3.5

4(8)

0

0.105

< 2.5

36(72)

43(86)

2.5–3.5

9(18)

7(14)

Microscopic hematuria

3(6)

3(6)

1.000

Hypercholesterolemia

30(60)

41(82)

0.032

Elevated Urea

9(18)

11(22)

0.617

Elevated Creatinine

4(8)

10(20)

0.084

Anaemia (Hb < 10)

14(28)

17 (34)

0.516